

Disclosures

Personal Commercial (19)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
<i>Self</i>			
ACI	Other - <i>Critical Events Committee</i>	Significant (>= \$5,000)	<i>Other</i>
Axon	Data Safety Monitoring Board	Modest (< \$5,000)	<i>Heart Failure and Cardiomyopathies</i>
Bayer Healthcare Pharmaceuticals	Consultant Fees/Honoraria	Modest (< \$5,000)	<i>Heart Failure and Cardiomyopathies</i>
BoehringerIngelheim	Data Safety Monitoring Board	Modest (< \$5,000)	<i>Heart Failure and Cardiomyopathies</i>
EBR Systems	Data Safety Monitoring Board	Modest (< \$5,000)	<i>Heart Failure and Cardiomyopathies</i>
Farady	Data Safety Monitoring Board	Modest (< \$5,000)	<i>Heart Failure and Cardiomyopathies</i>
Foundry Innovation and Research	Consultant Fees/Honoraria	Modest (< \$5,000)	<i>Heart Failure and Cardiomyopathies</i>
Impulse Dynamics	Data Safety Monitoring Board	Modest (< \$5,000)	<i>Heart Failure and Cardiomyopathies</i>
Ionis	Consultant Fees/Honoraria	Modest (< \$5,000)	<i>Heart Failure and Cardiomyopathies</i>
Ionis	Data Safety Monitoring Board	Modest (< \$5,000)	<i>Heart Failure and Cardiomyopathies</i>
Merck	Consultant Fees/Honoraria	Modest (< \$5,000)	<i>Heart Failure and Cardiomyopathies</i>
Mesoblast	Consultant Fees/Honoraria	Modest (< \$5,000)	<i>Heart Failure and Cardiomyopathies</i>
Novartis	Consultant Fees/Honoraria	Modest (< \$5,000)	<i>Heart Failure and Cardiomyopathies</i>
Rocket Pharma	Research/Research Grants ‡ <i>AAV9/LAMP2b Therapy for Danon Disease</i>	None (\$0)	<i>Heart Failure and Cardiomyopathies</i>
Tenaya	Consultant Fees/Honoraria	Modest (< \$5,000)	<i>Heart Failure and Cardiomyopathies</i>
Tenaya	Consultant Fees/Honoraria	Modest (< \$5,000)	<i>Heart Failure and Cardiomyopathies</i>
Vifor	Data Safety Monitoring Board	Modest (< \$5,000)	<i>Heart Failure and Cardiomyopathies</i>
Viking	Data Safety Monitoring Board	Modest (< \$5,000)	<i>Heart Failure and Cardiomyopathies</i>
Windtree	Data Safety Monitoring Board	None (\$0)	<i>Heart Failure and Cardiomyopathies</i>

Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

Personal Organizational or Other Non-Commercial (0)

No disclosures on record

Clinical Trial Enroller (0)

No disclosures on record

Institutional Financial Decision-Making Role (0)

No disclosures on record

Expert Witness Testimony (0)

No disclosures on record

‡ Commercial Funding Source | ‡ Trial Name

Agreement

Confidentiality, Disclosure and Assignment Agreement | Signed on 7/20/2023

URL for full agreement: <http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement>

Embargo | Signed on 7/20/2023

URL for full agreement: <http://disclosures.acc.org/Public/Definition/EmbargoAgreement>

On-Going Obligation Agreement | Signed on 7/20/2023

ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.